Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).
CONCLUSION: Since there was no statistical significance between the probucol and control groups despite a marked reduction of HDL-C, further studies on the clinical outcomes of probucol on top of conventional therapy may be necessary in the future (UMIN000003307).
PMID: 32336695 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
More News: Antidoxidants | Cardiology | Cardiovascular | Cholesterol | Coronary Heart Disease | Diabetes | Endocrinology | Heart | Heart Attack | Heart Disease | Heart Failure | Hypertension | Japan Health | Statin Therapy | Statistics | Stroke | Study | Thrombosis